Zai Lab: FDA grants fast track status to Zai Lab's lung cancer treatment

This ADC, which is currently under assessment in a global Phase Ia/IIb trial, has secured orphan drug designation from the agency for SCLC. According to the company, SCLC The post FDA grants fast track status to Zai Lab's lung cancer treatment appeared first on Pharmaceutical Business review.